Quarterly Survey: Diabetes GLP-1 Treatments and Mounjaro tirzepatide April 2023Ticker(s): LLY, NVO, AZN
The survey includes 20 Endocrinologists.
How many patients with Type 2 Diabetes do you have under your care?
Are you familiar with Mounjaro (tirzepatide) data to date?
How many of your patients are currently on a GLP-1 treatment?
How many of your patients are eligible for Mounjaro (tirzepatide)?
How many of your patients are on the following
GLP-1 treatments today?
- Mounjaro (tirzepatide):
- Semaglutide (Ozempic):
- Liraglutide (Victoza, Saxenda):
- Dulaglutide (Trulicity):
- Exenatide extended release (Bydureon bcise):
- Exenatide (Byetta):
How many patients have started Mounjaro (tirzepatide) in the past 90 days?
How many patients have discontinued Mounjaro (tirzepatide) in the past 90 days?
How many patients do you expect to use Mounjaro
(tirzepatide) at the following time points (cumulative)?
- 90 days/3 months:
- 1 year:
- 3 years:
How would you rate Mounjaro (tirzepatide) on the
following (where 1 is low and 5 is high)?
- Payor Access
Please elaborate on your view of Mounjaro (tirzepatide). Please be specific.
Do the side effects of Mounjaro (tirzepatide) limit your prescribing rate?
Which side effects limit your prescribing of Mounjaro (tirzepatide)?
What changes, if any, have you noticed with payor reimbursement and insurance for diabetes and weight loss treatments?
What is the most exciting new area of development in your specialty?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.